Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Oct;49(10):848–852. doi: 10.1136/jcp.49.10.848

Method for quantifying expression of functionally active topoisomerase II in patients with leukaemia.

A R Cattan 1, D Levett 1, E A Douglas 1, P G Middleton 1, P R Taylor 1
PMCID: PMC500783  PMID: 8943755

Abstract

AIMS: To produce a method to measure and quantify enzymatically active topoisomerase II in normal and neoplastic human cells. METHODS: A crude cell lysate from density separated mononuclear cells from either peripherial blood or bone marrow was prepared as a source of topoisomerases. Using the lysate, minicircles from the Crithedia kinetoplast DNA complex were decatenated before being separated by agarose gel electrophoresis and visualised using ethidium bromide/ultraviolet fluorescence. RESULTS: Cell number, sample volume and drug inhibition concentration required to produce reliable and reproducible assay conditions were established. Intra- and interassay standards were included which permitted the quantification of active topoisomerase II in matched peripheral blood, bone marrow, presentation, and relapse samples from patients with acute lymphoblastic leukaemia. Active topoisomerase II has been converted to a unit scale which has been used to compare topoisomerase II activities in cells from patients with normal blood and bone marrow samples. CONCLUSIONS: There was no change in topoisomerase II activities between samples taken at presentation and those taken during a recurrence. However, topoisomerase II activity in leukaemic blast populations was increased compared with topoisomerase II activity in normal cells.

Full text

PDF
848

Images in this article

851Image
on p.851

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. Burden D. A., Sullivan D. M. Phosphorylation of the alpha- and beta-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry. 1994 Dec 13;33(49):14651–14655. doi: 10.1021/bi00253a001. [DOI] [PubMed] [Google Scholar]
  3. Chen A. Y., Liu L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218. doi: 10.1146/annurev.pa.34.040194.001203. [DOI] [PubMed] [Google Scholar]
  4. Davies S. M., Robson C. N., Davies S. L., Hickson I. D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem. 1988 Nov 25;263(33):17724–17729. [PubMed] [Google Scholar]
  5. Deffie A. M., Batra J. K., Goldenberg G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 1989 Jan 1;49(1):58–62. [PubMed] [Google Scholar]
  6. Doyle L. A. Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol. 1994;34 (Suppl):S32–S40. doi: 10.1007/BF00684861. [DOI] [PubMed] [Google Scholar]
  7. Drake F. H., Zimmerman J. P., McCabe F. L., Bartus H. F., Per S. R., Sullivan D. M., Ross W. E., Mattern M. R., Johnson R. K., Crooke S. T. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem. 1987 Dec 5;262(34):16739–16747. [PubMed] [Google Scholar]
  8. Ellis A. L., Nowak B., Plunkett W., Zwelling L. A. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol. 1994;34(3):249–256. doi: 10.1007/BF00685085. [DOI] [PubMed] [Google Scholar]
  9. Erickson L. C. The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition. Semin Cancer Biol. 1991 Aug;2(4):257–265. [PubMed] [Google Scholar]
  10. Harker W. G., Slade D. L., Parr R. L., Feldhoff P. W., Sullivan D. M., Holguin M. H. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995 Apr 15;55(8):1707–1716. [PubMed] [Google Scholar]
  11. Harrison D. J. Molecular mechanisms of drug resistance in tumours. J Pathol. 1995 Jan;175(1):7–12. doi: 10.1002/path.1711750103. [DOI] [PubMed] [Google Scholar]
  12. Kaufmann S. H., Karp J. E., Jones R. J., Miller C. B., Schneider E., Zwelling L. A., Cowan K., Wendel K., Burke P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood. 1994 Jan 15;83(2):517–530. [PubMed] [Google Scholar]
  13. List A. F. Preclinical investigations of drug resistance. Curr Opin Oncol. 1995 Jan;7(1):19–27. [PubMed] [Google Scholar]
  14. McKenna S. L., West R. R., Whittaker J. A., Padua R. A., Holmes J. A. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia. 1994 Sep;8(9):1498–1502. [PubMed] [Google Scholar]
  15. McKenna S. L., Whittaker J. A., Padua R. A., Holmes J. A. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance? Leukemia. 1993 Aug;7(8):1199–1203. [PubMed] [Google Scholar]
  16. Melendy T., Ray D. S. Novobiocin affinity purification of a mitochondrial type II topoisomerase from the trypanosomatid Crithidia fasciculata. J Biol Chem. 1989 Jan 25;264(3):1870–1876. [PubMed] [Google Scholar]
  17. Mestdagh N., Pommery N., Saucier J. M., Hecquet B., Fournier C., Slomianny C., Teissier E., Hénichart J. P. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes. Anticancer Res. 1994 May-Jun;14(3A):869–874. [PubMed] [Google Scholar]
  18. Nitiss J. L., Liu Y. X., Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res. 1993 Jan 1;53(1):89–93. [PubMed] [Google Scholar]
  19. Patel S., Austin C. A., Fisher L. M. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line. Anticancer Drug Des. 1990 Feb;5(1):149–157. [PubMed] [Google Scholar]
  20. Proctor S. J., Taylor P., Thompson R. B., Finney R., Reid M. M., Hamilton P. J., Saunders P., Fail B., Dickinson A., Paul B. Acute lymphoblastic leukaemia in adults in the northern region of England--a study of 75 cases. Q J Med. 1985 Nov;57(223):761–774. [PubMed] [Google Scholar]
  21. Watt P. M., Hickson I. D. Structure and function of type II DNA topoisomerases. Biochem J. 1994 Nov 1;303(Pt 3):681–695. doi: 10.1042/bj3030681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Webb C. D., Latham M. D., Lock R. B., Sullivan D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 1991 Dec 15;51(24):6543–6549. [PubMed] [Google Scholar]
  23. Wells N. J., Hickson I. D. Human topoisomerase II alpha is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur J Biochem. 1995 Jul 15;231(2):491–497. doi: 10.1111/j.1432-1033.1995.tb20723.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES